AbbVie Inc Cash Flow Conversion Efficiency
AbbVie Inc cash flow conversion efficiency. Based on the latest financial reports, AbbVie Inc (ABBV) has a cash flow conversion efficiency ratio of -1.616x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($5.22 Billion) by net assets ($-3.23 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of AbbVie Inc (2010–2025)
Cash flow conversion efficiency of AbbVie Inc from 2010 to 2025. This chart illustrates how AbbVie Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ABBV live share price for real-time trading data and today's change.
AbbVie Inc Cash Flow Conversion Ratio Explained
AbbVie Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
AbbVie Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AbbVie Inc ranked by their cash flow conversion efficiency. Also see ABBV stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Chevron Corp
NYSE:CVX
|
0.013x |
|
UnitedHealth Group Incorporated
NYSE:UNH
|
0.104x |
|
Procter & Gamble Company
NYSE:PG
|
0.093x |
|
The Coca-Cola Company
NYSE:KO
|
0.144x |
|
Bank of America Corp
NYSE:BAC
|
0.139x |
|
Agricultural Bank of China Ltd Class A
SHG:601288
|
0.359x |
|
Oracle Corporation
NYSE:ORCL
|
0.340x |
|
Industrial and Commercial Bank of China Ltd
SHG:601398
|
-0.011x |
Annual Cash Flow Conversion Efficiency for AbbVie Inc (2010–2025)
The table below shows the annual cash flow conversion efficiency of AbbVie Inc from 2010 to 2025. Review AbbVie Inc (ABBV) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-3.23 Billion | $19.03 Billion | -5.895x | -205.45% |
| 2024-12-31 | $3.36 Billion | $18.81 Billion | 5.590x | +154.49% |
| 2023-12-31 | $10.40 Billion | $22.84 Billion | 2.197x | +52.24% |
| 2022-12-31 | $17.29 Billion | $24.94 Billion | 1.443x | -2.22% |
| 2021-12-31 | $15.44 Billion | $22.78 Billion | 1.476x | +9.88% |
| 2020-12-31 | $13.10 Billion | $17.59 Billion | 1.343x | +182.36% |
| 2019-12-31 | $-8.17 Billion | $13.32 Billion | -1.630x | -2.56% |
| 2018-12-31 | $-8.45 Billion | $13.43 Billion | -1.590x | -181.35% |
| 2017-12-31 | $5.10 Billion | $9.96 Billion | 1.954x | +28.66% |
| 2016-12-31 | $4.64 Billion | $7.04 Billion | 1.519x | -20.48% |
| 2015-12-31 | $3.94 Billion | $7.54 Billion | 1.910x | -6.25% |
| 2014-12-31 | $1.74 Billion | $3.55 Billion | 2.037x | +46.03% |
| 2013-12-31 | $4.49 Billion | $6.27 Billion | 1.395x | -26.05% |
| 2012-12-31 | $3.36 Billion | $6.34 Billion | 1.887x | +260.37% |
| 2011-12-31 | $11.93 Billion | $6.25 Billion | 0.524x | +65.22% |
| 2010-12-31 | $15.70 Billion | $4.98 Billion | 0.317x | -- |
About AbbVie Inc
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various c… Read more